These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23192914)

  • 1. Editorial comment on "Wada N, Kita M, Hashizume K, et al. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn 2013;32:1123-7".
    Oelke M
    Neurourol Urodyn; 2013 Nov; 32(8):1128-9. PubMed ID: 23192914
    [No Abstract]   [Full Text] [Related]  

  • 2. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Low Urin Tract Symptoms; 2015 Jan; 7(1):37-41. PubMed ID: 26663650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: A single center prospective study.
    De Nunzio C; Brassetti A; Proietti F; Gacci M; Serni S; Esperto F; Tubaro A
    Neurourol Urodyn; 2017 Nov; 36(8):2096-2100. PubMed ID: 28257560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
    Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients.
    Wu XJ; Zhi Y; Zheng J; He P; Zhou XZ; Li WB; Zhou ZS
    Urology; 2014 Mar; 83(3):539-43. PubMed ID: 24246318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
    Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
    Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.
    Becher E; Roehrborn CG; Siami P; Gagnier RP; Wilson TH; Montorsi F
    Prostate Cancer Prostatic Dis; 2009; 12(4):369-74. PubMed ID: 19901936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Generally effective for unstable bladder? Tamsulosin: application not limited to benign prostatic hyperplasia].
    Urologe A; 2003 Feb; 42(2):301-2. PubMed ID: 12739514
    [No Abstract]   [Full Text] [Related]  

  • 12. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    Witjes WP; Rosier FW; de Wildt MJ; van Iersel MP; Debruyne FM; de La Rosette JJ
    J Urol; 1996 Apr; 155(4):1317-23. PubMed ID: 8632523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
    Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 16. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
    Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
    Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies.
    Fusco F; Creta M; Imperatore V; Longo N; Imbimbo C; Lepor H; Mirone V
    Adv Ther; 2017 Apr; 34(4):773-783. PubMed ID: 28255867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
    Abrams P
    Eur Urol; 1997; 32(1):39-46. PubMed ID: 9266230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.